Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Voss

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Pharmaceutical Statistics|November 21, 2018
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapiesSteffen Unkel, Marjan Amiri, Norbert Benda, et al.
BMJ Open Respiratory Research|September 14, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)Toby M Maher, Shervin Assassi, Arata Azuma, et al.
Blood|July 10, 2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyHartmut Döhner, Michael Lübbert, Walter Fiedler, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
Annals of Hepatology|April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trialsDonald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Pharmaceutical Statistics|November 21, 2018
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapiesSteffen Unkel, Marjan Amiri, Norbert Benda, et al.
BMJ Open Respiratory Research|September 14, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)Toby M Maher, Shervin Assassi, Arata Azuma, et al.
Blood|July 10, 2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyHartmut Döhner, Michael Lübbert, Walter Fiedler, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
Annals of Hepatology|April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trialsDonald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
Pageof 3